Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have been offered as promising targets for the treatment of cancers. Immune checkpoint inhibitors (ICIs)targeting PD-1, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooshkaki, Omid, Derakhshani, Afshin, Hosseinkhani, Negar, Torabi, Mitra, Safaei, Sahar, Brunetti, Oronzo, Racanelli, Vito, Silvestris, Nicola, Baradaran, Behzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352976/
https://www.ncbi.nlm.nih.gov/pubmed/32580338
http://dx.doi.org/10.3390/ijms21124427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352976/
https://www.ncbi.nlm.nih.gov/pubmed/32580338
http://dx.doi.org/10.3390/ijms21124427

Ejemplares similares